Article Sidebar

Submitted
October 21, 2021
Accepted
October 28, 2022
Published
October 29, 2022
Download
PDF
Statistic
Read Counter : 309 Download : 298

Downloads

Download data is not yet available.

Main Article Content

Abstract

The COVID-19 pandemic has disrupted the supply chain of domestic pharmaceutical raw materials, where 95% of the fulfillment of raw materials relies on imports. Amid difficulties in meeting raw materials, the pharmaceutical sub-sector companies have become one of the sectors of choice for investors throughout 2020, in line with the sentiment of the COVID-19 pandemic. As one of the prima donnas’ sectors during pandemic, financial reports presented by pharmaceutical sector should report the actual condition of the company. This study aims to empirically examine the differences in accrual earnings management before and after the COVID-19 pandemic in pharmaceutical sub-sector companies in Indonesia. To evaluate changes in accrual earnings management in the period before the COVID-19 pandemic, namely in 2019 and after the COVID-19 pandemic, namely in 2020, the Paired Sample T-test was used. The findings of this study show that there is no average difference between accrual earnings management before COVID-19 (Pre-test) and after COVID-19 (Post-test), indicating that COVID-19 has no impact on earnings management practices in the pharmaceutical sub-sector companies in Indonesia. The deteriorating global economic conditions caused by the COVID-19 pandemic do not necessarily encourage managers to carry out aggressive earnings management. The pharmaceutical sub-sector companies that have become the center of attention of investors during this pandemic, as a result the company’s performance shown in the financial statements does not make managers aggressively try to manipulate their financial statements.

Keywords

Accrual Earnings Management COVID-19 Paired Sample T-test Pharmaceutical Sub-sector

Article Details

License

Copyright (c) 2022 Widyaningsih Azizah, Hotman Fredy, Fathoni Zoebaedi

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Author retains the copyright and grants the journal the right of first publication of the work simultaneously licensed under the Creative Commons Attribution-ShareAlike 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal

Author is able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book) with the acknowledgement of its initial publication in this journal.

Author is permitted and encouraged to post his/her work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).

 Creative Commons Attribution-ShareAlike (CC BY-SA)

Creative Commons License

Jurnal Akuntansi is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

 

How to Cite
Azizah, W., Fredy, H., & Zoebaedi, F. (2022). COVID-19: Accrual Earnings Management Practices in Pharmaceutical Companies in Indonesia. Jurnal Akuntansi, 12(3), 223–238. https://doi.org/10.33369/jakuntansi.12.3.223-238
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Azizah, W. (2017a). Opportunistic Perspective off Accrual And Real Earnings Management in Indonesia. IOSR Journal of Business and Management, 19(11), 1–05. https://doi.org/10.9790/487X-1911070105
  2. Azizah, W. (2017b). Trend and Tradeoff Between Accrual Earnings Management And Real Earnings Management in Indonesia. Media Riset Akuntansi, Auditing & Informasi, 17(2), 159–172. https://doi.org/10.25105/mraai.v17i2.2079
  3. Azizah, W. (2021). Covid-19 in Indonesia: Analysis of Differences Earnings Management in the First Quarter. Jurnal Akuntansi, 11(1), 23–32. https://doi.org/10.33369/j.akuntansi.11.1.23-32
  4. Azizah, W., Bantasyam, S., & Sinaga, L. (2020). Indonesia ’ s LQ45 Index : Tax Discount Facility and Earnings Management. IOSR Journal of Business and Management (IOSR-JBM), 22(8), 27–31. https://doi.org/10.9790/487X-2208032731
  5. Azizah, W., Wahyoeni, S. I., & Zoebaedi, F. (2021). Covid-19 and Accrual Earnings Management In Indonesia in the Second Quarter. International Journal of Business and Management Invention (IJBMI), 10(9), 33–39. https://doi.org/10.35629/8028-1009013339
  6. Azizah, W., Zoebaedi, F., Bantasyam, S., & Rizky Oktaviani, Y. (2019). Earnings Management in Indonesia: Are Women Always Under? IOSR Journal of Business and Management, 21(11), 42–46. https://doi.org/10.9790/487X-2111014246
  7. Azizah, W., Zoebaedi, F., & Yatim, M. R. (2020). Income Smoothing : Does Firm Size Matter in Indonesia ? IOSR Journal of Business and Management (IOSR-JBM), 22(11), 21–23. https://doi.org/10.9790/487X-2211042123
  8. Badan Pusat Statistik. (2020). Pertumbuhan Ekonomi Indonesia Triwulan IV-2020. Jakarta: BPS. https://www.bps.go.id/pressrelease/2021/02/05/1811/ekonomi-indonesia-2020-turun-sebesar-2-07-persen--c-to-c-.html. Accessed on April, 4th 2021
  9. Dechow, Patricia M., Richars G. Sloan. dan Amy P. Sweeney. (1995). Detecting Earning Management. The Accounting Review. Volume 70: 193-225
  10. Ghozali, Imam. (2015). Ekonometrika (Teori, Konsep dan Aplikasi dengan SPSS). Badan Penerbit Universitas Diponegoro: Semarang.
  11. Hamdani, Trio. 2020. Menperin: Farmasi Terdampak Corona, 60% Bahan Baku dari China. https://finance.detik.com/industri/d-4934297/menperin-farmasi-terdampak-corona-60-bahan-baku-dari-china Accessed on March, 24th 2021.
  12. Indrawati, M., & Brahmayanti, I. A. S. (2021). Pengaruh Kinerja Keuangan Dan Makro Ekonomi Terhadap Harga Saham Selama Pandemi Covid-19 Pada Perusahaan Sub-Sektor Farmasi Di Bursa Efek Indonesia. JEM17: Jurnal Ekonomi Manajemen, 6(1), 65–82. https://doi.org/10.30996/jem17.v6i1.5276
  13. Linhares, F. S., Costa, F. M. da, & Beiruth, A. X. (2018). Earnings management and investment efficiency. Revista Brasileira de Gestao de Negocios Review of Business Management, 20(2), 295–310. https://doi.org/10.7819/rbgn.v20i2.3180
  14. Majid, M., Lysandra, S., Masri, I., & Azizah, W. (2020). Pengaruh Kecakapan Manajerial Terhadap Manajemen Laba Akrual dan Riil. Jurnal Ilmiah Akuntansi Dan Manajemen (JIAM), 16(1), 70–84. https://doi.org/https://doi.org/10.31599/jiam.v16i1.115
  15. Maulana, Arif. 2021. Mengapa Virus Corona Bisa Bermutasi? Ini Penjelasannya. https://www.unpad.ac.id/2020/12/mengapa-virus-corona-bisa-bermutasi-ini-penjelasannya/. Accessed on June, 3th 2021
  16. Nurfitriyani, Annisa. 2020. Harga Melonjak Gila-gilaan, Saham Sektor Farmasi Ketiban Untung Virus Corona?. https://www.wartaekonomi.co.id/read274820/harga-melonjak-gila-gilaan-saham-sektor-farmasi-ketiban-untung-virus-corona. Accessed on August, 1st 2021.
  17. Orazalin, N. (2019). Board Gender Diversity, Corporate Governance, and Earnings Management: Evidence from An Emerging Market. Gender in Management, 35(1), 37–60. https://doi.org/10.1108/GM-03-2018-0027
  18. Panjaitan, D. K., & Muslih, M. (2019). MANAJEMEN LABA: UKURAN PERUSAHAAN, KEPEMILIKAN MANAJERIAL DAN KOMPENSASI BONUS (Studi pada Perusahaan Manufaktur yang Terdaftar di Bursa Efek Indonesia Tahun 2014-2017). MANAJEMEN LABA: UKURAN PERUSAHAAN, KEPEMILIKAN MANAJERIAL DAN KOMPENSASI BONUS (Studi Pada Perusahaan Manufaktur Yang Terdaftar Di Bursa Efek Indonesia Tahun 2014-2017), 11(1), 1–20. https://doi.org/10.17509/jaset.v11i1.15726
  19. Prasetyo, Y., Amyulianthy, R., & Azizah, W. (2021). Pengaruh Pengungkapan Islamic Social Reporting Dan Corporate Governance Terhadap Accruals Earning Management Pada Perbankan Syariah Di Indonesia. Al-Mal: Jurnal Akuntansi Dan Keuangan Islam, 2(1), 1–16. http://103.88.229.8/index.php/al-mal/article/view/21-01-2021
  20. Rahayu, Arfyana Citra dan Dewi, Herlina Kartika. 2019. Sektor farmasi bepotensi untung di 2019, simak rekomendasi analis berikut ini. https://investasi.kontan.co.id/news/sektor-farmasi-bepotensi-untung-di-2019-simak-rekomendasi-analis-berikut-ini. Accessed on August, 21th 2021
  21. Ren, L. L., Wang, Y. M., Wu, Z. Q., Xiang, Z. C., Guo, L., Xu, T., Jiang, Y. Z., Xiong, Y., Li, Y. J., Li, X. W., Li, H., Fan, G. H., Gu, X. Y., Xiao, Y., Gao, H., Xu, J. Y., Yang, F., Wang, X. M., Wu, C., … Wang, J. W. (2020). Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chinese Medical Journal, 133(9), 1015–1024. https://doi.org/10.1097/CM9.0000000000000722
  22. Romantis, O., Heriansyah, K., & Azizah, W. (2020). Pengaruh Perencanaan Pajak Terhadap Manajemen Laba yang Dimoderasi Oleh Penurunan Tarif Pajak (Diskon Pajak). Jurnal Ilmiah Akuntansi Dan Manajemen (JIAM), 16(1), 85–95. https://doi.org/https://doi.org/10.31599/jiam.v16i1.116
  23. Scott, R. William. 2015. Financial Accounting Theory. Seventh Edition. United States : Pearson.
  24. Sumartiningtyas, Holy Kartika Nurwigati. 2021. 3 Vaksin COVID-19 di Indonesia, Perbedaan Vaksin Sinovac, AstraZeneca dan Sinopharm. https://www.kompas.com/sains/read/2021/05/03/190200023/3-vaksin-COVID-19-di-indonesia-perbedaan-vaksin-sinovac-astrazeneca-dan?page=all. Accessed on April, 30th 2021
  25. Ulfah, Finna U. 2020. Jadi Pilihan Investor Tahun Ini, Bagaimana Nasib Saham Sektor Farmasi pada 2021?. https://market.bisnis.com/read/20201230/7/1337083/jadi-pilihan-investor-tahun-ini-bagaimana-nasib-saham-sektor farmasi-pada-2021. Accessed on April, 3th 2021
  26. Vollono, C., Rollo, E., Romozzi, M., Frisullo, G., Servidei, S., Borghetti, A., & Calabresi, P. (2020). Focal Status Epilepticus as Unique Clinical Feature of COVID-19: A Case Report. Europian Journal of Epilepsy, 78(2020), 109–112. Retrieved from https://doi.org/10.1016/j.seizure. 2020.04.009
  27. Wang, Y., & Campbell, M. (2012). Corporate governance, earnings management, and IFRS: Empirical evidence from Chinese domestically listed companies. Advances in Accounting , 28 (1), 189–192
  28. Wiguna, Dewa Ketut Sudiarta dan Fardaniah, Risbiani. 2020. Ada Sektor yang Meraup Untung Saat Wabah Corona. https://www.antaranews.com/berita/1406226/sri-mulyani-ada-sektor-yang-meraup-untung-saat-wabah-corona. Accessed on August, 4th 2021
  29. Worldometers. (2020). Reported Cases and Deaths By Country Or Territory. https:// https://www.worldometers.info/coronavirus/. Accessed on March, 23th 2021.
  30. WHO.(2020). Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed on June, 2nd 2020.
  31. Yang, L., & Ren, Y. (2020). Moral Obligation, Public Leadership, and Collective Action for Epidemic Prevention and Control: Evidence from the Corona Virus Disease 2019 (COVID-19) Emergency. International Journal of Environmental Research and Public Health, 17(8), 1–16. https://doi.org/10.3390/ijerph17082731.